Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting

IMR OpenIR

	Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting
其他题名	Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting
	Zhai HengBo 1; Liu Jun 1; Dong ZhiChao 1; Wang DongXia 1; Zhang Bo 1
	2017
发表期刊	Chinese Medical Journal
ISSN	0366-6999
卷号	130 期号:12 页码:1418-1423
摘要	Background: It is currently believed that triple oral antithrombotic therapy in patients with atrial fibrillation (AF) after percutaneous coronary intervention (PCI) should be recommended if there are no contraindications. However, selecting triple therapy for AF patients undergoing PCI is still challenging when bleeding risk is considered. This study aimed to investigate the current use of oral anticoagulants (Vitamin K antagonists VKA) and perform prognostic analysis in real-world patients with AF undergoing coronary stenting. Methods: A total of 276 consecutive coronary artery disease (CAD) patients with or without AF undergoing coronary stenting were retrospectively evaluated and analyzed. The univariate and multivariate analyses were conducted to explore the current use of VKA and prognosis of patients with AF undergoing coronary stenting. The primary end-point was composite of all-cause death, nonfatal recurrent myocardial infarction, stroke, serious bleeding events, unplanned repeat revascularization, and worsening heart failure at 12-month follow-up after coronary stenting. Results: AF patients undergoing coronary stenting have more clinical concomitant diseases. Only 9.0% AF patients after coronary stenting received triple antithrombotic therapy (VKA, aspirin, and clopidogrel) at discharge. AF was independently associated with increased risk of the 12-month composite end-points (relative risk = 5.732, 95% confidence interval 1.786–18.396, P = 0.003). Conclusions: In real-life AF patients undergoing coronary stenting, guideline-recommended VKA was less used. AF patients had adjusted worse prognosis during 12-month follow-up after discharge. It is of utmost importance to improve the current status of oral anticoagulants use.
其他摘要	Background： It is currently believed that triple oral antithrombotic therapy in patients with atrial fibrillation （AF） after percutaneous coronary intervention （PCI） should be recommended if there are no contraindications. However, selecting triple therapy for AF patients undergoing PCI is still challenging when bleeding risk is considered. This study aimed to investigate the current use of oral anticoagulants （Vitamin K antagonists VKA） and perform prognostic analysis in real-world patients with AF undergoing coronary stenting. Methods： A total of 276 consecutive coronary artery disease （CAD） patients with or without AF undergoing coronary stenting were retrospectively evaluated and analyzed. The univariate and multivariate analyses were conducted to explore the current use of VKA and prognosis of patients with AF undergoing coronary stenting. The primary end-point was composite of all-cause death, nonfatal recurrent myocardial infarction, stroke, serious bleeding events, unplanned repeat revascularization, and worsening heart failure at 12-month follow-up after coronary stenting. Results： AF patients undergoing coronary stenting have more clinical concomitant diseases. Only 9.0% AF patients after coronary stenting received triple antithrombotic therapy （VKA, aspirin, and clopidogrel） at discharge. AF was independently associated with increased risk of the 12-month composite end-points （relative risk = 5.732, 95% confidence interval 1.786-18.396, P = 0.003）. Conclusions： In real-life AF patients undergoing coronary stenting, guideline-recommended VKA was less used. AF patients had adjusted worse prognosis during 12-month follow-up after discharge. It is of utmost importance to improve the current status of oral anticoagulants use.
关键词	Antithrombotic Therapy Medicine R Atrial Fibrillation Coronary Artery Disease Percutaneous Coronary Intervention Prognosis
收录类别	CSCD
语种	英语
资助项目	[Health and Family Planning Commission of Liaoning, China] ; [Science and Technology Program of Dalian, China]
CSCD记录号	CSCD:6009463
引用统计	被引频次：1[CSCD] [CSCD记录]
文献类型	期刊论文
条目标识符	http://ir.imr.ac.cn/handle/321006/157620
专题	中国科学院金属研究所
作者单位	1.Dalian Med University, Affiliated Hosp 1, Dept Cardiol, Dalian 116011, Liaoning, Peoples R China 2.中国科学院金属研究所
推荐引用方式 GB/T 7714	Zhai HengBo,Liu Jun,Dong ZhiChao,et al. Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting[J]. Chinese Medical Journal,2017,130(12):1418-1423.
APA	Zhai HengBo,Liu Jun,Dong ZhiChao,Wang DongXia,&Zhang Bo.(2017).Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting.Chinese Medical Journal,130(12),1418-1423.
MLA	Zhai HengBo,et al."Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting".Chinese Medical Journal 130.12(2017):1418-1423.